Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
KKR & Co. Inc., also known as Kohlberg Kravis Roberts & Co., agreed to buy a stake in Cotiviti to accelerate innovation and growth. The American investment firm is acquiring the asset from Veritas Capital Fund Management, L.L.C., a private equity company based in New York City.
KKR & Co. is set to invest $11 billion to acquire a stake in Cotiviti. This amount would be one of the most significant new PEF transactions. On Wednesday, Feb. 14, the company said that KKR and Veritas Capital will have equal shares in the health tech firm once the deal is completed.
Financing for the Deal
The acquisition will boost KKR's portfolio of healthcare analytics investments. According to Axios, the agreement will include $5 billion worth of loans that JPMorgan would manage.
This arrangement with a leading investment company is said to be a major win for the traditional banking sector, which has mostly been yielding buyout financing to private credit companies.
JPMorgan will help KKR with financing its Cotiviti acquisition through loans. In any case, the deal is expected to be completed within the second quarter of this year.
KKR and Veritas Capital's Plans
The Wall Street Journal reported that KKR and Veritas Capital's deal now ranks among the most extensive negotiations in recent times. This is because buyout firms have decelerated dealmaking after the Federal Reserve started marking up interest rates in 2022, making debt to fund acquisitions more expensive and challenging to secure.
Meanwhile, under the agreement, KKR and Veritas will also hand out considerable capital to help accelerate innovation while funding investments for growth. They may expand their business, introduce new product development, and work together on some tech-related opportunities.
"I am excited to continue our partnership with Veritas and welcome KKR as a new partner. Since initially partnering with Veritas in 2016, we have dramatically expanded our scale and enhanced our value proposition to our customers," Cotiviti's chairman, president, and chief executive officer, Emad Rizk, M.D., said in a press release. "I look forward to collaborating with both KKR and Veritas to leverage our highly differentiated solutions to improve the cost and quality within the healthcare system."
Photo by: Cotiviti Press Room
